FOLCEPRI® (Etarfolatide) Molecular Imaging

Designed to identify tumors that may respond to folate-targeted therapy

Folcepr®i (Etarfolatide) is a folate-targeted molecular imaging agent that is being developed to non-invasively identify tumors that express folate receptors and that may respond to folate-targeted therapy. It is being co-developed as the companion imaging agent to Vynfinit® (vintafolide) and EC1456 (folate-tubulysin).

Development Stage

Folcepri® (etarfolatide) imaging has been a component of more than 13 clinical studies in patients with cancers of the ovary, endometrium, kidney, pituitary, lung, and refractory solid tumors; and has been administered to more than 1000 patients.